ClinicalTrials.Veeva

Menu

A Longitudinal Observational Follow-up of the PRECEPT Study Cohort (PostCEPT)

P

Parkinson Study Group (PSG)

Status

Unknown

Conditions

Parkinson Disease

Study type

Observational

Funder types

Other
NETWORK
Industry
Other U.S. Federal agency
NIH

Identifiers

NCT00605163
U01NS050095_PostCEPT
NINDS 5 U01NS050095-02
U01NS050095 (U.S. NIH Grant/Contract)

Details and patient eligibility

About

The purpose of this study is to longitudinally follow consenting clinical trial participants who participated in PRECEPT (A Randomized, Double Blind, Placebo Controlled, Dose Finding Study to Assess the Efficacy and Safety of CEP 1347 in Patients With Early Parkinson's Disease). The study will assess the clinical and imaging outcomes relevant to the natural history of Parkinson's disease (PD), as well as determine early biomarkers of the disease.

Enrollment

530 estimated patients

Sex

All

Ages

30+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Participation in the PRECEPT study
  • Willing and able to give informed consent

Exclusion criteria

  • Patients will be excluded from participating in the the study if either of the criteria stated above is not met

Trial contacts and locations

55

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems